Cardiovascular Systems, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardiovascular Systems, Inc.
Abbott Buys CSI To Add Peripheral And Coronary Atherectomy Technologies
CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Enliven Takes Precision Oncology Ambitions Public In Merger With Imara
The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top candidate tovinontrine.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Replidyne, Inc.
- Shturman Cardiology Systems, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.